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Lymphoma was a common complication of HIV infection in the pre-antiretroviral era, and the incidence of HIV-associated
lymphomahasdroppeddramaticallysincetheintroductionofcombinationantiretroviraltherapy(cART)inresource-richregions.
Conversely,lymphomaisanincreasinglycommoncomplicationofHIVinfectioninresource-limitedsettingswheretheprevalence
of HIV infection is high. Relatively little is known, however, about the true incidence and optimal treatment regimens for HIV-
associated lymphoma in resource-poor regions. We review the epidemiology, diagnosis, and treatment of HIV-associated non-
Hodgkin lymphoma in developing nations and highlight areas forfurther research that may beneﬁt care in both settings. Examples
include risk modiﬁcation and dose modiﬁcation of chemotherapy based on HIV risk factors, improving our understanding of
the current burden of disease through national cancer registries, and developing cost-eﬀective hematopathological diagnostic
strategies to optimize care delivery and maximize use of available chemotherapy.
1.Introduction
An association between the acquired immunodeﬁciency syn-
drome (AIDS) and lymphoma was ﬁrst suggested in 1982
after four young men in San Francisco with severe immun-
odeﬁciency were diagnosed with a “Burkitt-like lymphoma”
[1, 2]. Since that time, HIV has been identiﬁed as the caus-
ative agent of the underlying immunodeﬁciency and non-
Hodgkin lymphoma (NHL) was designated as an AIDS-
deﬁningmalignancy[3].Whilemostoftheearlydescriptions
of the emerging immunodeﬁciency syndrome were reported
in patients living in the United States, most of the burden
of HIV disease now aﬀects resource-limited nations, with
approximately two-thirds of HIV-positive individuals living
in sub-Saharan Africa and only 8% within Western nations
[4]. The discovery and widespread use of combination
antiretroviral therapy (cART) in resource-rich countries has
both decreased the incidence of HIV-associated lymphoma
and improved its prognosis [5, 6]. While the availability
of cART has improved in resource-poor nations due to
extraordinary recent eﬀorts, similar changes in the incidence
and outcome of HIV-associated lymphomas have not yet
been noted. Therefore, increased eﬀorts should be dedicated
to improving the diagnosis, supportive care, and treatment
of this disorder in these nations.
2. History andEpidemiology
TheincidenceofthethreeAIDS-deﬁningNHLs,diﬀuselarge
B-cell lymphoma (DLBCL), primary CNS lymphoma, and
Burkitt lymphoma (BL), increased steadily in the United
States between 1981 and 1990, at which time the incidence
rate leveled oﬀ and began declining with the widespread
availability of cART in 1996 [7]. Over 25,000 Americans with
HIV have been diagnosed with NHL since the beginning of
the HIV pandemic [8].
In Africa, the AIDS epidemic was ﬁrst reported by
Clumeck et al. and Van De Perre et al. in 1984 when they2 Advances in Hematology
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Figure 1: Odds Ratios (ORs) with 95% Conﬁdence Intervals (CIs)
for the association between NHL and HIV infection in sub-Saharan
Africa.
d e s c r i b e dag r o u po fA f r i c a n sc a r e df o ri nB e l g i u mw i t h
profound immunosuppression and a series of patients in
Kigali, Rwanda with infectious complications or generalized
Kaposi sarcoma, respectively [9, 10]. Nearly equal numbers
of men and women were reported in these articles, in
contrast to the predominately male epidemiology described
early in the United States HIV experience. The incidence of
NHL in sub-Saharan Africa did not increase as markedly
early in the HIV epidemic when compared to the increase
seen in the US HIV population. This has been attributed to
the higher rate of infectious complications that were seen
in HIV-infected patients in resource-limited nations, which
prevented the subsequent development of malignancies [11].
This decreased incidence may also simply reﬂect under-
reporting, attributable to more limited pathology services
in combination with diﬀerences in the epidemiology of
adenopathy in sub-Saharan Africa. Since the most common
empiric clinical diagnosis of persistent lymphadenopathy is
tuberculosis and not lymphoma, many cases may have gone
unnoticed without biopsy conﬁrmation [12]. By the mid-
1990s,anincreaseinlymphomariskassociatedwithHIVwas
noted and at present most studies report a 5-6-fold increased
risk for development of NHL in HIV-infected individuals
living in Africa as seen in Figure 1 [13–16].
On average, patients in Africa present with HIV-asso-
ciated complications at a higher CD4 count compared to
those in resource-rich nations. With current supportive care,
the burden of HIV-associated NHL is currently estimated at
about 15,000 per year in the equatorial belt of Africa alone
[17, 18]. The true incidence is believed to be higher, due
to continued limitations in diagnosis and presentation to
medical care, though the HIV-associated risk for NHL still
d o e sn o ts e e mt ob ea sh i g ha si nr e s o u r c e - r i c hn a t i o n si n
the pre-cART era. Data from the International Agency for
Research on Cancer shows that the incidence of NHL in
most countries of Africa exceeds that of the USA by 2–5-
fold. Although cancer registry data in Africa do not routinely
capture the HIV status of new cancer cases, Figure 2 clearly
illustrates that the incidence of NHL is highest in African
countries with a high prevalence of HIV infection, though
part of this trend may reﬂect improved diagnosis associated
with HIV clinics.
The Kampala Cancer Registry is one of the oldest con-
tinually operating cancer registries in Africa and one of two
which are WHO-certiﬁed. This registry was created in 1954
and enables an estimation of the impact of HIV infection
on rates of malignancy in the area and serves as a tool for
ongoingresearch[19].TheincidenceofNHLinKampalahas
increased6.7%annuallyinmenand11%annuallyinwomen
since the beginning of the HIV pandemic [20]. Linking HIV
and cancer registries in Uganda showed that the incidence
of NHL was 6.7-fold higher among HIV-infected persons
in Uganda compared with those who are HIV negative,
lending credence to the hypothesis that the increase in NHL
incidence in sub-Saharan Africa is in part fueled by the HIV
pandemic.
Comprehensive data on survival after a diagnosis of
NHL in HIV-positive persons are lacking in both resource-
rich and resource-poor regions. However, two recent studies
highlight the discrepancies in survival between patients in
these two settings. In the USA, 47% of HIV-positive persons
diagnosed with non-CNS NHL were alive 2 years after their
diagnosis [21], which was nearly identical to the survival
among HIV-positive Ugandans who received cART [22].
Of note, however, is the fact that 100% of HIV-positive
Ugandans with NHL who failed to receive cART died within
one year of NHL diagnosis, highlighting the importance of
the comanagement of HIV and cancer.
Increasing the number of such registries and the quality
of data collected will contribute signiﬁcantly to improving
our understanding of the epidemiology of lymphoma in
Africa. Collecting information on HIV-associated malignan-
cies at clinics that distribute antiretrovirals is one potential
way to increase the available data.
3.Diagnosis
A necessary complement to expanded cancer registry data
in resource-poor nations is continued improvement in diag-
nostic accuracy, especially of hematological neoplasms. The
accurate diagnosis of lymphomas can be challenging, even
for pathologists in developed nations without hematopatho-
logicalspecialization.Diagnosticmodiﬁcationsweremadein
20% of a series of submitted lymphoma cases in the United
Kingdom after central review. After evaluation of associated
clinical data in each of the cases, the authors concluded that
clinical management likely would have diﬀered in about half
of the cases with diagnostic discrepancies [23]. Similarly, the
diagnosis of lymphoma in developing nations is challenging
and signiﬁcant modiﬁcations in ﬁnal diagnosis have been
reported after hematopathology review. A retrospective
analysis of 207 NHL cases in Kenya resulted in the histologic
reclassiﬁcation of 41% of the cases [24]. An additional study
by Parkins and authors reviewed 150 cases of suspected
lymphoproliferative disorders from two teaching hospitals
in Ghana at the time of diagnosis. After this review,
modiﬁcationsweremadetothediagnosesof44%ofpatients,
and alterations in the subsequent clinical management in
31% of the 150 patients as a result. Some of the ﬁnalAdvances in Hematology 3
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Figure 2: Incidence of non-Hodgkin lymphoma in Africa compared to the United States. Data courtesy of GLOBOCAN 2008.
diagnoses in this group included nasopharyngeal carcinoma
and tuberculosis, with marked diﬀerences in management
resulting [25]. The rates of signiﬁcant diagnostic changes
do vary between studies, however. In a prospective trial of
combination chemotherapy in HIV-associated lymphoma in
East Africa, pathological review led to changes in diagnosis
in only 6% of the 32 patients with tissue samples available.
Additionally, when the outcomes of patients with patho-
logical conﬁrmation were compared to those that did not
undergo pathological review, no diﬀerences in outcome were
noted [26].
A so p t i m a lt h e r a p i e sb e c o m em o r ev a r i e df o re a c h
lymphoma subtype, it is likely that the clinical signiﬁcance
of diagnostic accuracy will increase. An initial attempt to
improve this diagnostic accuracy in a cost-eﬀective manner
was recently reported by Naresh and colleagues through a
description of a diagnostic algorithm for Burkitt lymphoma.
They described a three-tiered method for diagnosis that
involved increasing numbers of immunohistochemical tests
in each tier if the diagnosis remained unclear. They were
able to conﬁrm a diagnosis of BL versus DLBCL in 82% of
the cases using the ﬁrst phase of studies (CD10, bcl2, and
morphology)andin92%ofcaseswiththeadditionoftesting
for Ki-67, CD38, and CD44 [27]. This type of data can be
used to guide developing health systems in prioritizing the
diagnostic procedures that are most cost-eﬀective.
The beneﬁt of immunohistochemistry, not routinely
available in resource-limited regions at present, extends
beyond its assistance in conﬁrming a diagnosis in this age
of increasing numbers of targeted therapies. Discovering
immunophenotypic diﬀerences of lymphomas in varying
patientpopulations maypromotediscoveryofnoveltargeted
agents as well as further evaluation of current agents in
clinical trials, even at the present time. For example,
Tumwine and authors described the immunohistochemical
features of 119 cases of lymphoma in Kampala, Uganda. 37%
of the Burkitt lymphoma cases were CD30 positive [28],
twice the rate of 18% noted in a similar series from the
United Kingdom [29]. With the recent development of an
antibody-chemotherapy conjugate that targets CD30, such a
ﬁnding could impact treatment outcomes in this population
[30].
4. Chemotherapy in the Pre-cART Era
At the present time, standard therapy for HIV-associated
lymphoma in Africa does not include targeted therapy, such
as rituximab, as current medication costs are prohibitive.
Therefore, treatment is delivered with standard cytotoxic
agents alone. Because of the similarities between the current
patient population in resource-limited nations and patients
in resource-rich nations in the pre-cART era, a historical
review of chemotherapy for HIV-associated lymphomas is
helpful for identifying potential areas of further study.
Initially, the treatment of AIDS-associated lymphoma in
the United States achieved complete response (CR) rates
of 53% with combination chemotherapy usually involving
CHOP (cyclophosphamide, doxorubicin, vincristine, and
prednisone), though these responses were tempered by a
rate of relapse of 54%. Additionally, signiﬁcant infectious
complications were noted in 42% of the cohort, which con-
tributed to a mortality rate of 85% during a three-year study
by Ziegler and colleagues reported in 1984 [31].
The next generation of chemotherapy trials in AIDS-
related lymphoma studied more aggressive chemotherapy
combinations in recognition of the fact that such cases typi-
cally presented at a more advanced stage, had a higher grade
at presentation, an increased risk of relapse, and an increased
frequency of extranodal disease compared with non-AIDS-
related lymphomas. For example, Gill and authors compared4 Advances in Hematology
M-BACOD (high-dose methotrexate, bleomycin, doxoru-
bicin, cyclophosphamide, vincristine, and dexamethasone)
with an even more intensive regimen using high-dose
cytarabine and high-dose methotrexate in combination with
other agents. Rates of complete remission were 54% and
33% in the two groups, respectively, and the overall survival
was 11 months in the M-BACOD group compared to 6
months in the cytarabine/methotrexate arm. This trend
towards shorter survival was attributed to a higher rate of
opportunisticinfectionsinthecytarabine/methotrexatearm,
with more than 75% developing this complication [32].
Similarly, Kaplan and colleagues found a high-dose regimen,
COMET-A (cyclophosphamide, vincristine, methotrexate,
etoposide, and high-dose cytarabine), was associated with
decreased overall survival when compared to standard
therapy such as CHOP in patients with HIV-associated
lymphoma. Outcomes in both of these studies were best
predicted by pretreatment CD4 count, performance status
and presence of extranodal disease [33]. Since infectious
complications overwhelmed any potential advantage to these
aggressive regimens, less-intensive chemotherapy regimens
were studied next.
A 1997 study by the AIDS Clinical Trials Group (ACTG
142) therefore compared lower-dose m-BACOD to stan-
dard dose m-BACOD with GM-CSF support. The lower-
dose regimen was associated with decreased hematological
toxicity and similar rates of response. CR rate in the low-
dose arm was 39%, compared to 52% in the standard-dose
arm while median overall survival was 35 weeks compared
to 31 weeks, respectively. Neither of these diﬀerences was
statistically signiﬁcant [34]. The survival impact of regimen-
related toxicity in the treatment of HIV-associated lym-
phomas in the pre-cART era was further clariﬁed by a trial
conducted by Mounier and colleagues where the selection
of chemotherapy was adjusted based on clinical risk factors
present at diagnosis. Subjects treated between 1993 and 1999
were stratiﬁed based on ECOG performance status of 2–4,
a prior clinical diagnosis of AIDS, and a CD4 count less
than 100cells/µL. Patients with none of these risk factors
received one of two aggressive chemotherapy regimens and
no diﬀerences in overall survival were noted between 4 cycles
of CHOP (cyclophosphamide, doxorubicin, vincristine, and
prednisone)and3cyclesofACVBP(doxorubicin,cyclophos-
phamide, vindesine, bleomycin, and prednisolone). Patients
with one risk factor received either standard-dose or low-
dose CHOP, again without any diﬀerence in overall survival.
The third group, with either 2 or 3 risk factors, received
either 4 cycles of low-dose CHOP or 12 cycles of vincristine
and prednisolone. There were no diﬀerences in overall
survival between regimens in any of the risk groups, though
lymphoma-speciﬁc outcomes were improved in the more
aggressive arms of each subset. It should be noted that after
1996 most patients were started on cART, and this subset
composed about one-third of the entire study cohort. While
cART did decrease the number of patients with 2-3 risk
factors and improve overall survival, it did not lead to any
signiﬁcant diﬀerences between chemotherapy regimens in
risk-stratiﬁed patients [35]. Therefore, a decrease in regimen
intensity and dose adjustment by hematological parameters
for high-risk patients should be considered when treating
lymphoma in patients not on cART.
The balance of minimizing myelotoxicity and infectious
risk while optimizing lymphoma therapy has an even
narrower therapeutic window in resource-limited nations
due to the decreased availability of supportive care measures
such as broad-spectrum antibiotics and the high rates of
baseline cytopenias. Concurrent use of other supportive
medications may be a major contributor to the high rates
of cytopenias in African patients with HIV infection. For
example, in a study of 498 patients started on antiretroviral
therapy in Cote d’Ivoire, the observed 24% rate of grade 3-
4 neutropenia was ascribed to the combined administration
of trimethoprim/sulfamethoxazole and zidovudine (AZT).
While the neutropenia usually resolved with discontinuation
of the TMP/SMX, the omission of this prophylactic therapy
increased the risk of infectious complications, a risk that
would likely increase further in the setting of cytotoxic
chemotherapy [36]. This infectious risk was demonstrated
clinically in an early trial of chemotherapy for HIV-
associated Burkitt lymphoma in Africa. This cohort of BL
patients older than 16 years old, treated between 1993 and
1996, experienced a treatment-related mortality rate of 46%
with a median overall survival of 15 weeks [37].
5. Chemotherapy in the cART Era
After the discovery and widespread use of cART in resource-
rich countries, overall survival in HIV-associated lymphoma
improved, in one study from an average of 6 months to
20 months [6], and more aggressive treatment regimens
were once again considered. With the additional immuno-
logical support enabled with cART, the next major trial
of chemotherapy in HIV-associated lymphoma compared
CHOP to rituximab-CHOP combination therapy and was
reported by Kaplan and authors as part of the AIDS
Malignancy Consortium trial 010. This study found a trend
towards increased eﬃcacy (CR rate of 58% versus 47%)
in the rituximab plus chemotherapy arm, however, also
noted a signiﬁcantly increased risk of treatment-related
death in the combination arm of 14% compared to 2%.
This increased risk of death was attributed to increased
infectious complications during the treatment course and,
on additional analysis, seemed to predominate in patients
with CD4 counts <50cells/µL. This ﬁnding supports the
importance of risk stratiﬁcation by CD4 count, even in
patients on cART at the start of chemotherapy [38].
For a time, this report led to decreased use of ritux-
imab therapy in patients with HIV-associated lymphoma.
However, additional data was recently provided by Dunleavy
and colleagues [39] and Sparano and colleagues [40]i na
pair of articles published in 2010. In these studies, ritux-
imab therapy was used to treat HIV-positive patients with
DLBCL and NHL, respectively. There were no treatment-
associated infectious deaths noted in the study by Dunleavy,
supporting the safety of rituximab in this setting. Addi-
tionally, this study demonstrated other methods aimed at
decreasing the duration of associated immunosuppression
andmyelotoxicitywithchemotherapyregimens.TheauthorsAdvances in Hematology 5
utilized a decreased number of cycles of infusional EPOCH
in combination with “dose-dense” rituximab (given on
days 1 and 5). The EPOCH was dose adjusted based on
hematological parameters per protocol prior to each cycle
of therapy, thereby regulating the average neutrophil nadir.
Second, the study utilized interim FDG-PET scans to guide
the number of chemotherapy cycles, with one cycle given
after the ﬁrst negative PET-CT. By using this strategy, about
80% of the patients received only three cycles of therapy
with the highest number of received cycles being 5, delivered
in 12% of the subjects. The CR rate was 91% with 5-
year PFS and OS of 84% and 68%, respectively. Of the
10 deaths on study, half were due to lymphoma and 5
occurred while subjects remained in remission. 3 of these
deaths were due to opportunistic infection and 1 developed
a secondary Burkitt lymphoma. The immediate application
of this treatment regimen in resource-limited settings is
prevented for multiple reasons. First, a lack of hospital
beds and hospital staﬀ relative to the large numbers of
patients in need of treatment prevents delivery of ﬁve days
of infusional EPOCH. Second, while this regimen is dose
adjustedforhematologicalparameters,itisdeliveredwithG-
CSF support, a therapy that is not available in most resource-
poor settings. Third, PET scans, and even CT scans, are not
available in routine clinical practice at the present time to
rationally select patients that may safely receive fewer cycles
of chemotherapy.
Even with these limitations, however, several principles
can be incorporated to improve care in resource-poor set-
tings. Dose adjustment has been investigated in trials of
chemotherapy in sub-Saharan Africa with some success.
One such study, and the ﬁrst prospective trial investigating
chemotherapy for HIV-associated lymphomas in Africa, was
performedbyMwandaandcolleagues,reportedin2009[26].
This study utilized a dose-modiﬁed oral chemotherapy regi-
men based on a United States trial that was completed before
the availability of antiretroviral therapy [41]. The dose-
modiﬁedregimenincludedlomustine(50mg/m2 day1,cycle
1 only), etoposide (100mg/m2 days 1–3), cyclophosphamide
(100mg/m2 days 22–26), and procarbazine (100mg/m2 days
22–26).AstheinitialregimenrequiredG-CSFsupport,doses
were decreased in the protocol to prevent this requirement.
Additional modiﬁcations during therapy were also outlined,
inamannersimilartotheinfusionalEPOCHregimen.These
adjustments led to a 50% dose reduction in all medications
for an absolute WBC count less than 3,000cells/µLo r
a platelet count under 100,000cells/µL. For WBC count
less than 1,500cells/µL or platelets under 50,000cells/µL
doses were held until counts improved. If counts did not
improve within three weeks, subjects were removed from
the protocol—though this did not occur in any subjects on
protocol. Median CD4 count in the 49-patient cohort was
198cells/µL, 37% of patients were on antiretroviral therapy,
and most had a history of previous opportunistic infection.
65% of the patients completed the two cycles determined
by the protocol and a 6% treatment-related mortality was
noted during the study, a signiﬁcant improvement from
previous studies. The reported CR rate was 58% with 78%
having an objective response, numbers that are comparable
to pre-cART studies in resource-rich nations. Median overall
survival was 12 months, though a large variance was noted
inpatientsoncARTcomparedtonoretroviraltherapywitha
medianoverallsurvivalinthelattergroupofabout6months.
This study serves as an example that prospective chemo-
therapy trials can be completed in resource-limited settings.
It also identiﬁes additional beneﬁts from such studies, which
may aid the management of HIV-associated lymphoma in
resource-rich nations. First, this study by Mwanda and
colleagues in East Africa is notable for its inclusion of female
participants. In contrast to the >85% male composition of
many of the other major trials in the ﬁeld [6, 35, 39, 40] this
cohort was composed of 60% women. Second, the chem-
otherapy regimen was composed of some medications that
are known to cross the blood-brain barrier (lomustine, pro-
carbazine) and without additional intrathecal therapy the
rate of CNS relapse (6%) was similar compared to other
trials performed prior to widespread availability of cART.
Further investigation of the use of CNS-active agents in HIV-
associated lymphoma therapy may be warranted, especially
in situations where delivery of intrathecal therapy is diﬃcult.
6. Supportive Care
Since platelet transfusions are currently not routinely avail-
able in most resource-limited nations [42], conditions exist
to study chemotherapy regimens that decrease the need for
transfusion and to evaluate adjunctive therapies that may
decreasebleedingcomplicationsinthesettingofthrombocy-
topenia such as aminocaproic acid [43]. This could improve
our understanding of the optimal management of patients
in resource-rich nations that have an objection to receiving
blood products.
Another aspect of the regimen used by Mwanda that
maywarrantfurtherstudyistheavoidanceofcorticosteroids,
even though they are known to be active lympholytics.
The rationale for not including corticosteroids in the study
regimen is avoidance of potential exacerbation of concurrent
Kaposi sarcoma (KS) and HHV-8 infection, an important
consideration as the prevalence of KS is highest in East
Africa [44]. Similarly, increased immunosuppression due
to corticosteroid administration could be associated with
increased toxicity in patients with HIV due to other in-
fectious comorbidities. The increased risk of reactivation
or infection with M. tuberculosis is a consideration when
balancing the risks and beneﬁts of corticosteroids in high
prevalence regions [45]. Hepatitis B virus (HBV) is another
infection that has been shown to reactivate more commonly
whencorticosteroidsareincludedinchemotherapyregimens
for lymphoma [46] and is well known to reactivate during
rituximab therapy if viral prophylaxis is not administered
in previously exposed patients [47]. There is a 13% rate of
detectable serum hepatitis B DNA in patients admitted to
Mulago Hospital in Uganda, [48] which could enable further
clariﬁcation of the magnitude of risk associated with HBV
reactivationcomparedwiththetreatmentbeneﬁtofcorticos-
teroids.Theseresultscouldimproveclinicaldecision-making
concerning the ideal chemotherapy regimen to use in the
setting of concurrent HIV and HBV infection.6 Advances in Hematology
7. Conclusions
While a large portion of the improvements in treatment of
HIV-associated lymphomas in resource-limited nations will
occur as a result of earlier diagnosis, increased access to
cART, and optimal treatment of concurrent infectious dis-
ease, signiﬁcant opportunities to improve the hematological
management of such cases also exist. Some of these advances
may also beneﬁt patients with HIV-associated lymphoma in
resource-richnations. Examples include improvedrisk mod-
iﬁcation and dose modiﬁcation of chemotherapy, improved
diagnostic capabilities with eventual implementation of
targeted therapies based on the immunophenotypic proﬁle,
and an increased understanding of optimal supportive care
for patients with infectious comorbidities.
The cost of cancer care is often raised as a barrier to
increasing access in resource-limited settings. On the con-
trary, however, it is the cost of inaction that is estimated to be
much more signiﬁcant. The Global Task Force on Expanded
Access to Cancer Care and Control estimated that the world
could have saved $131 billion in 2010 by investing in cancer
treatment and prevention to limit the associated disability-
adjusted life years [49]. Similarly, the 2011 World Economic
Forum report identiﬁed noncommunicable diseases as a
global economic threat, framing health care as an investment
instead of simply expenditure [50]. This perspective, in
combination with the fact that “cancer now kills more
people each year in (low and middle-income countries) than
AIDS, tuberculosis, and malaria combined” [51] highlights
the ethical and ﬁnancial imperative to improve the care of
lymphoma globally and serves as a call to action for the
hematology community.
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